Literature DB >> 25437582

Cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture.

Qiang Li1, Lin-Zhong Zhu, Ren-Jie Yang, Xu Zhu.   

Abstract

To investigate which anticancer drugs and combination of dual drugs could further promote the inhibition of cell growth in vitro against HCC cell line (HepG2) in the hypoxic and hyponutritional culture medium (HHCM) mimicked the different scenarios of transcatheter arterial chemoembolization (TACE). The cells of hepatocellular carcinoma (HCC) treated by TACE suffered various hypoxia and hyponutrition. The cells were treated for 2 hours, 4 hours, 6 hours, and 24 hours, respectively, using 10 drugs including epirubicin (EPI), cisplatin (DDP), mitomycin-C (MMC), oxaliplatin (OXA), hydroxycamptothecin (HCPT), 5-fluorouracil (5-FU), gemcitabine (GEM), docetaxel (DTX), thiotepa (TSPA), and pemetrexed disodium (PEM) in 4 concentrations of HHCM (5%, 10%, 25%, and 50%, respectively) mimicking the scenario of TACE and were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells treated with combinations of dual drugs for 24 hours were also tested. The sensitive drugs with inhibition rates more than 30% were EPI, MMC, HCPT, OXA, and PEM in 4 types of HHCMs. The sensitivity of the cells to treatment with drugs for 24 hours was significantly higher than the sensitivity of the cells to treatment with drugs for 2 hours in 5%, 10%, and 25% HHCM. The sensitivity of the combination of dual drugs was no more than the sensitivity of the single drug with higher sensitivity in 4 concentrations of HHCM. EPI, MMC, HCPT, OXA, and PEM exhibited cytotoxic activity against HepG2 cells in various hypoxia and hyponutrition states. Prolonging the time of exposure could increase the sensitivity of drug, and the combination of dual drugs cannot enhance the cytotoxic effect.

Entities:  

Keywords:  Chemosensitivity test; Hepatocellular carcinoma; Hypoxia; MTT assay; Transcatheter arterial chemoembolization

Mesh:

Substances:

Year:  2014        PMID: 25437582      PMCID: PMC4254235          DOI: 10.9738/INTSURG-D-14-00073.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  32 in total

Review 1.  Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective.

Authors:  Kenichi Takayasu
Journal:  Jpn J Clin Oncol       Date:  2012-03-09       Impact factor: 3.019

Review 2.  Local-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Laura Crocetti
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

Review 3.  Arterially directed therapies for hepatocellular carcinoma.

Authors:  Rajesh P Shah; Karen T Brown; Constantinos T Sofocleous
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

4.  Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor.

Authors:  Hirohide Matsuura; Toshihiro Ichiki; Jiro Ikeda; Kotaro Takeda; Ryohei Miyazaki; Toru Hashimoto; Eriko Narabayashi; Shiro Kitamoto; Tomotake Tokunou; Kenji Sunagawa
Journal:  Hypertension       Date:  2011-08-08       Impact factor: 10.190

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Kei Sawara; Yasuhiro Miyamoto; Yukiho Kasai; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

7.  Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury.

Authors:  Mateo Ziu; Lauren Fletcher; Shushan Rana; David F Jimenez; Murat Digicaylioglu
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

8.  Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition.

Authors:  Liang Liu; Zheng-Gang Ren; Yuan Shen; Xiao-Dong Zhu; Wei Zhang; Wei Xiong; Yi Qin; Zhao-You Tang
Journal:  Cancer Sci       Date:  2009-09-14       Impact factor: 6.716

9.  Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.

Authors:  Wiratchanee Mahavorasirikul; Vithoon Viyanant; Wanna Chaijaroenkul; Arunporn Itharat; Kesara Na-Bangchang
Journal:  BMC Complement Altern Med       Date:  2010-09-28       Impact factor: 3.659

Review 10.  The possible mechanisms underlying the impairment of HIF-1α pathway signaling in hyperglycemia and the beneficial effects of certain therapies.

Authors:  Haijuan Xiao; Zhenyang Gu; Guoxing Wang; Tongfeng Zhao
Journal:  Int J Med Sci       Date:  2013-08-22       Impact factor: 3.738

View more
  2 in total

1.  Relationship between ADH2 Arg47His variation and hepatocellular carcinoma susceptibility: a meta analysis.

Authors:  Shuzhen Liu; Yongchun Cui; Baohong Yang; Ping Chai; Zheng Su; Qianqian Zhang; Dejie Zheng; Rui Li; Guohua Yu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Docetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction for targeted tumor therapy in MHCC-H cells.

Authors:  Yue Zhang; Ruijiao Chang; Muqiong Li; Kun Zhao; Hongzhi Zheng; Xiaodong Zhou
Journal:  Onco Targets Ther       Date:  2016-08-01       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.